Aspire Biopharma Holdings Inc (ASBP)

$5.61 -0.26 (-4.43%)
Market Cap 887,000.00
Revenue (ttm) 10,000.00
Net Income (ttm) -24.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -244,800.00%
Debt to Equity Ratio -0.44
Volume 115,700
Avg Vol 558,461
Day's Range N/A - N/A
Shares Out 167,000.00
Stochastic %K 68%
Beta 0.21
Analysts Strong Buy
Price Target N/A

Company Profile

Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, such as melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semag...

Industry: Biotechnology
Sector: Healthcare
Phone: 908 987 3002
Address:
23150 Fashion Drive, Suite 232, Estero, United States
Imemuna_Yokonai
Imemuna_Yokonai May. 15 at 8:44 PM
$ASBP Lol... Buzz Bomb sales haven't quite picked up yet. 😂
0 · Reply
Arnie_510
Arnie_510 May. 15 at 7:08 PM
$ASBP 𝗧𝗵𝗲 𝗞𝗶𝗻𝗴 𝗼𝗳 𝗥𝗲𝘃𝗲𝗿𝘀𝗲 𝗦𝘁𝗼𝗰𝗸 𝗦𝗽𝗹𝗶𝘁𝘀 January 2026 1 for 40 reverse split. May 2026 1 for 30 reverse split.
0 · Reply
Pennystockmadness
Pennystockmadness May. 15 at 6:13 PM
$ASBP here we go again, same exact pattern!
0 · Reply
Arnie_510
Arnie_510 May. 15 at 5:23 PM
$ASBP Is there a 1 for 500 reverse split in the future?
0 · Reply
Arnie_510
Arnie_510 May. 15 at 5:21 PM
$ASBP Anything below 10¢ a share is considered a good buy. But 5¢ is even better.
0 · Reply
Arnie_510
Arnie_510 May. 15 at 5:16 PM
$ASBP The price, ”she’s a no move”, was it halted?
0 · Reply
Arnie_510
Arnie_510 May. 15 at 5:11 PM
$ASBP Wait, I thought they did their buyback on the 8th, the Friday before the reverse split occured, to manipulate the price up so it opened higher on Monday. Oh crap, my bad, disregard.
0 · Reply
Arnie_510
Arnie_510 May. 15 at 4:45 PM
$ASBP They must have some clown with a sandwich sign walking the streets of Puerto Rico peddling this crap. It’s either that or the stock trades itself because no one here is fool enough to buy it. Certainly not at these prices, maybe 20 cents.
0 · Reply
Arnie_510
Arnie_510 May. 15 at 2:44 PM
$ASBP Dead in the water, all systems shutting down. Cash booth out of service, ATM is next. Unless they can convince people they have a magic potion to pour in your gas tank that’ll get you 100 mpg they’re done.
0 · Reply
Capark12
Capark12 May. 15 at 2:03 PM
$ASBP should reverse today. had great momuntum
0 · Reply
Latest News on ASBP
Aspire Biopharma Holdings Inc trading halted, news pending

2026-05-08T23:50:15.000Z - 6 days ago

Aspire Biopharma Holdings Inc trading halted, news pending

Aspire Biopharma to effect 1-for-30 reverse stock split

2026-05-07T17:59:49.000Z - 8 days ago

Aspire Biopharma to effect 1-for-30 reverse stock split

Aspire Biopharma Holdings, Inc. Announces Approval Of Reverse Stock Split Ratio

May 7, 2026, 11:00 AM EDT - 8 days ago

Aspire Biopharma Holdings, Inc. Announces Approval Of Reverse Stock Split Ratio

Aspire Biopharma announces $5M share repurchase plan

2026-04-27T12:40:32.000Z - 18 days ago

Aspire Biopharma announces $5M share repurchase plan

Aspire Biopharma Announces $5.0 Million Share Repurchase Program

Apr 27, 2026, 8:30 AM EDT - 18 days ago

Aspire Biopharma Announces $5.0 Million Share Repurchase Program

Aspire Biopharma closes final tranche of $21M private placement

2026-04-20T14:15:12.000Z - 25 days ago

Aspire Biopharma closes final tranche of $21M private placement

Aspire Biopharma Announces Closing of Second and Final Tranche of $21 Million Private Placement by Select Investors; Secures Commitment Letter for $22.5M Credit Facility to Fund the DCS Acquisition

Apr 20, 2026, 8:30 AM EDT - 25 days ago

Aspire Biopharma Announces Closing of Second and Final Tranche of $21 Million Private Placement by Select Investors; Secures Commitment Letter for $22.5M Credit Facility to Fund the DCS Acquisition

Buzz Bomb brand ambassador to attempt fastest 100-mile treadmill run

2026-04-17T12:15:44.000Z - 4 weeks ago

Buzz Bomb brand ambassador to attempt fastest 100-mile treadmill run

Aspire Biopharma's Buzz Bomb(TM) Caffeine Company's Brand Ambassador, Ashley Paulson, to Attempt Fastest 100-Mile Treadmill Run at 2026 Boston Marathon Expo

Apr 17, 2026, 8:00 AM EDT - 4 weeks ago

Aspire Biopharma's Buzz Bomb(TM) Caffeine Company's Brand Ambassador, Ashley Paulson, to Attempt Fastest 100-Mile Treadmill Run at 2026 Boston Marathon Expo

Aspire Biopharma enters LOI to acquire Dura Driver Control Systems for $30M

2026-04-16T12:48:21.000Z - 4 weeks ago

Aspire Biopharma enters LOI to acquire Dura Driver Control Systems for $30M

Aspire Biopharma Has Entered Into a Letter of Intent to Acquire a Leading Global Automotive Supplier With a 100+ Year History and $200M+ in 2025 Revenue

Apr 16, 2026, 8:30 AM EDT - 4 weeks ago

Aspire Biopharma Has Entered Into a Letter of Intent to Acquire a Leading Global Automotive Supplier With a 100+ Year History and $200M+ in 2025 Revenue

Aspire Biopharma subsidiary announce sales, marketing agreement with Interwest

2026-04-15T12:22:20.000Z - 4 weeks ago

Aspire Biopharma subsidiary announce sales, marketing agreement with Interwest

Aspire Biopharma's Buzz Bomb Caffeine Company Partners with Interwest Brokerage to Accelerate Retail Expansion

Apr 15, 2026, 8:00 AM EDT - 4 weeks ago

Aspire Biopharma's Buzz Bomb Caffeine Company Partners with Interwest Brokerage to Accelerate Retail Expansion

Aspire Biopharma subsidiary signs retail distribution agreement with TruLife

2026-03-19T12:57:13.000Z - 2 months ago

Aspire Biopharma subsidiary signs retail distribution agreement with TruLife

Aspire Biopharma's Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail Expansion

Mar 19, 2026, 8:00 AM EDT - 2 months ago

Aspire Biopharma's Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail Expansion

Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales Director

Mar 17, 2026, 8:30 AM EDT - 2 months ago

Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales Director

Aspire Biopharma's Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026

Mar 12, 2026, 8:00 AM EDT - 2 months ago

Aspire Biopharma's Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026

Aspire Biopharma launches BUZZ BOMB Covenience Store Pack

2026-03-10T12:51:37.000Z - 2 months ago

Aspire Biopharma launches BUZZ BOMB Covenience Store Pack

Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack

Mar 10, 2026, 8:30 AM EDT - 2 months ago

Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack

Aspire Biopharma, Microsize partner for sublingual alprazolam formulation

2026-03-03T13:30:58.000Z - 2 months ago

Aspire Biopharma, Microsize partner for sublingual alprazolam formulation

Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief

Mar 3, 2026, 8:00 AM EST - 2 months ago

Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief

Aspire Biopharma’s Buzz Bomb announces expansion of social media footprint

2026-02-25T14:02:56.000Z - 2 months ago

Aspire Biopharma’s Buzz Bomb announces expansion of social media footprint

Aspire Biopharma's Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon Sponsorship

Feb 25, 2026, 8:30 AM EST - 2 months ago

Aspire Biopharma's Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon Sponsorship

Aspire Biopharma regains compliance with Nasdaq listing requirements

2026-02-20T13:05:16.000Z - 3 months ago

Aspire Biopharma regains compliance with Nasdaq listing requirements

Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements

Feb 20, 2026, 8:00 AM EST - 3 months ago

Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements

Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record

Feb 19, 2026, 8:00 AM EST - 3 months ago

Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record

Aspire Biopharma files to sell 159.1M shares of common stock for holders

2026-02-17T21:25:29.000Z - 3 months ago

Aspire Biopharma files to sell 159.1M shares of common stock for holders

Aspire Biopharma files provisional patent application for Meclizine formulation

2026-02-17T13:51:22.000Z - 3 months ago

Aspire Biopharma files provisional patent application for Meclizine formulation

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R))

Feb 17, 2026, 8:30 AM EST - 3 months ago

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R))

Aspire Biopharma appoints Phillip Balatsos to board of directors

2026-02-13T13:10:38.000Z - 3 months ago

Aspire Biopharma appoints Phillip Balatsos to board of directors

Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors

Feb 13, 2026, 8:00 AM EST - 3 months ago

Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors

Aspire Biopharma files patent application for sublingual ondansetron formulation

2026-02-12T13:38:49.000Z - 3 months ago

Aspire Biopharma files patent application for sublingual ondansetron formulation

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))

Feb 12, 2026, 8:00 AM EST - 3 months ago

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))

Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements

Feb 11, 2026, 7:45 AM EST - 3 months ago

Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements

Aspire Biopharma regains compliance with Nasdaq minimum bid price rule

2026-02-10T13:25:12.000Z - 3 months ago

Aspire Biopharma regains compliance with Nasdaq minimum bid price rule

Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Feb 10, 2026, 8:00 AM EST - 3 months ago

Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit

Feb 5, 2026, 8:00 AM EST - 3 months ago

Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit

Aspire Biopharma’s Buzz Bomb partners with Blue Shark Beverages

2026-02-03T13:45:21.000Z - 3 months ago

Aspire Biopharma’s Buzz Bomb partners with Blue Shark Beverages

Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution

Feb 3, 2026, 8:00 AM EST - 3 months ago

Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution

Aspire Biopharma Secures Agreement with Microsize for Development of Novel Sublingual Aspirin

Jan 29, 2026, 8:00 AM EST - 3 months ago

Aspire Biopharma Secures Agreement with Microsize for Development of Novel Sublingual Aspirin

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Powder Formulation of Clopidogrel (Generic Plavix(R)) to Address Gastric Bleeding Risks

Jan 27, 2026, 8:00 AM EST - 3 months ago

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Powder Formulation of Clopidogrel (Generic Plavix(R)) to Address Gastric Bleeding Risks

Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity

Jan 22, 2026, 8:00 AM EST - 4 months ago

Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity

Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign

Jan 21, 2026, 8:00 AM EST - 4 months ago

Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief

Jan 20, 2026, 8:00 AM EST - 4 months ago

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief

Aspire Biopharma Announces Reverse Stock Split

Jan 14, 2026, 8:00 AM EST - 4 months ago

Aspire Biopharma Announces Reverse Stock Split

Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)

Jan 7, 2026, 8:00 AM EST - 4 months ago

Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)

Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine

Dec 18, 2025, 8:30 AM EST - 5 months ago

Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine

Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

Dec 12, 2025, 5:00 PM EST - 5 months ago

Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

Aspire Biopharma Provides Q3 2025 Business Update

Dec 4, 2025, 9:00 AM EST - 5 months ago

Aspire Biopharma Provides Q3 2025 Business Update

Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Dec 2, 2025, 9:00 AM EST - 5 months ago

Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member

Nov 26, 2025, 9:00 AM EST - 6 months ago

Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member

Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin

Nov 6, 2025, 9:00 AM EST - 6 months ago

Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin

Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform

Oct 6, 2025, 8:30 AM EDT - 7 months ago

Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform

Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025

Oct 3, 2025, 11:30 AM EDT - 8 months ago

Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025

Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication

Oct 1, 2025, 8:30 AM EDT - 8 months ago

Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication

Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product

Sep 17, 2025, 8:30 AM EDT - 8 months ago

Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product

Aspire Biopharma Announces Initial Production Order of Two Million Servings (100,000 20-packs) of BUZZ BOMB(TM) Pre-Workout Supplement

Sep 16, 2025, 8:30 AM EDT - 8 months ago

Aspire Biopharma Announces Initial Production Order of Two Million Servings (100,000 20-packs) of BUZZ BOMB(TM) Pre-Workout Supplement

Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Sep 3, 2025, 8:30 AM EDT - 9 months ago

Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aug 18, 2025, 8:30 AM EDT - 9 months ago

Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20

Aug 14, 2025, 8:00 AM EDT - 9 months ago

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20

Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

Aug 13, 2025, 9:10 AM EDT - 9 months ago

Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement

Jul 31, 2025, 8:30 AM EDT - 10 months ago

Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement

Aspire Biopharma Holdings, Inc. Announces CEO Transition

Jul 30, 2025, 7:45 PM EDT - 10 months ago

Aspire Biopharma Holdings, Inc. Announces CEO Transition

Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

Jul 22, 2025, 10:45 AM EDT - 10 months ago

Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement

Jul 9, 2025, 8:30 AM EDT - 11 months ago

Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement

Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Jun 24, 2025, 8:30 AM EDT - 11 months ago

Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer

Jun 10, 2025, 8:30 AM EDT - 1 year ago

Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer

Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025

May 28, 2025, 8:30 AM EDT - 1 year ago

Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025

Imemuna_Yokonai
Imemuna_Yokonai May. 15 at 8:44 PM
$ASBP Lol... Buzz Bomb sales haven't quite picked up yet. 😂
0 · Reply
Arnie_510
Arnie_510 May. 15 at 7:08 PM
$ASBP 𝗧𝗵𝗲 𝗞𝗶𝗻𝗴 𝗼𝗳 𝗥𝗲𝘃𝗲𝗿𝘀𝗲 𝗦𝘁𝗼𝗰𝗸 𝗦𝗽𝗹𝗶𝘁𝘀 January 2026 1 for 40 reverse split. May 2026 1 for 30 reverse split.
0 · Reply
Pennystockmadness
Pennystockmadness May. 15 at 6:13 PM
$ASBP here we go again, same exact pattern!
0 · Reply
Arnie_510
Arnie_510 May. 15 at 5:23 PM
$ASBP Is there a 1 for 500 reverse split in the future?
0 · Reply
Arnie_510
Arnie_510 May. 15 at 5:21 PM
$ASBP Anything below 10¢ a share is considered a good buy. But 5¢ is even better.
0 · Reply
Arnie_510
Arnie_510 May. 15 at 5:16 PM
$ASBP The price, ”she’s a no move”, was it halted?
0 · Reply
Arnie_510
Arnie_510 May. 15 at 5:11 PM
$ASBP Wait, I thought they did their buyback on the 8th, the Friday before the reverse split occured, to manipulate the price up so it opened higher on Monday. Oh crap, my bad, disregard.
0 · Reply
Arnie_510
Arnie_510 May. 15 at 4:45 PM
$ASBP They must have some clown with a sandwich sign walking the streets of Puerto Rico peddling this crap. It’s either that or the stock trades itself because no one here is fool enough to buy it. Certainly not at these prices, maybe 20 cents.
0 · Reply
Arnie_510
Arnie_510 May. 15 at 2:44 PM
$ASBP Dead in the water, all systems shutting down. Cash booth out of service, ATM is next. Unless they can convince people they have a magic potion to pour in your gas tank that’ll get you 100 mpg they’re done.
0 · Reply
Capark12
Capark12 May. 15 at 2:03 PM
$ASBP should reverse today. had great momuntum
0 · Reply
Arnie_510
Arnie_510 May. 15 at 1:59 PM
$ASBP Nobody’s buying this shit, they’ll have to find a lower trading range to keep the ATM in service.
0 · Reply
Arnie_510
Arnie_510 May. 15 at 1:54 PM
$ASBP If you purchased in the $5 range a psychological evaluation is in order. Or any range above $1 dollar.
0 · Reply
Arnie_510
Arnie_510 May. 15 at 1:30 PM
$ASBP Good Morning Future Bag Holders Many longtime bag holders eventually cut their losses while new bag holders are lured in to replace them. Nasdaq requires a certain amount of shareholders to remain compliant.
0 · Reply
Pennystockmadness
Pennystockmadness May. 15 at 12:38 PM
$ASBP nice!!!!! Looking for $6+ today!
0 · Reply
markymark75
markymark75 May. 15 at 12:25 PM
$ASBP
0 · Reply
Evilalchemist
Evilalchemist May. 15 at 11:00 AM
$ASBP But overall, 2026 was disastrous for shareholders because dilution and financing pressure overwhelmed the positive news flow. All of the positive news has been considered misleading and fluff in efforts to keep cash burn flowing for board members.
0 · Reply
Evilalchemist
Evilalchemist May. 15 at 10:56 AM
$ASBP ASBP had an extremely poor 2026 performance overall — even by penny stock standards. Key numbers: * The stock reportedly started 2026 around $5.28 adjusted for reverse splits and later traded near $0.15, a collapse of roughly -97% year-to-date at one point. * Its market cap fell from tens of millions to roughly under $1 million during parts of 2026. * The company also executed multiple reverse splits, including a 1-for-40 reverse split in January 2026 and another announced 1-for-30 reverse split in May 2026
0 · Reply
Evilalchemist
Evilalchemist May. 15 at 10:53 AM
$ASBP absolutely has to have the record for worse performing stock in 2025 and 2026 thus far
0 · Reply
Psikus
Psikus May. 14 at 11:14 PM
$ASBP If you are here to quick trade this you are very welcome to but if you thinking about investing you better read previous posts so you won’t lose money. 2 RS this year alone, very high risk. If you are a gambler go on and throw some chips but what Arnie is saying it’s all true.
0 · Reply
Arnie_510
Arnie_510 May. 14 at 9:49 PM
$ASBP I don’t believe anything these people are dishing out. Lots of red flags raising too many questions about their legitimacy. 1. Sublingual aspirin bullshit 2. Packaged caffeine powder 3. LOI to purchase auto parts company 4. Virtual business office, relocated from Puerto Rico to Florida. 5. Back to back reverse stock splits 6. Other things I won’t discuss, still building my case
0 · Reply
Arnie_510
Arnie_510 May. 14 at 9:10 PM
$ASBP We’re watching them closely, have not forgotten about your posts @Evilalchemist
0 · Reply
Arnie_510
Arnie_510 May. 14 at 9:06 PM
$ASBP Don’t worry @CaptainCihan we’re gonna get the SEC’s attention come hell or high water. Who on earth does a 1 for 40 reverse stock split in January (fucked investors) then another 1 for 30 reverse stock split a couple of months later? Screwing investors a second time. They have nothing to offer but bullshit!
1 · Reply